Elevated Lp A clinical trials

Explore recruiting elevated lp a clinical trials.

Recruiting elevated lp a studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Elevated Lp A trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)

Slovakia, Poland, Greece, Netherlands, Germany, Czechia +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

Spain, Hungary, Portugal, Greece, Germany, Italy +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with established cardiovascular disease

Hungary, Czechia, Sweden, Italy, Netherlands, Germany +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single arm, open label extension (OLE), multicenter study to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in patients with cardiovascular disease who have successfully completed the Frontiers Apheresis parent study

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A single arm, multicenter, open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in participants who completed the parent Lp(a)HORIZON trial

Belgium, Slovenia, Spain, Hungary, France, Poland +14 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Elevated Lp A trials by city

Elevated Lp A in Toronto Elevated Lp A in Vancouver Elevated Lp A in Montreal Elevated Lp A in Calgary Elevated Lp A in Edmonton Elevated Lp A in Ottawa Elevated Lp A in Winnipeg Elevated Lp A in Quebec City Elevated Lp A in Hamilton Elevated Lp A in Kitchener Elevated Lp A in London Elevated Lp A in Halifax Elevated Lp A in New York Elevated Lp A in Los Angeles Elevated Lp A in Chicago Elevated Lp A in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease